Dr. Corr has more than 30 years of pharmacology and pharmaceutical development experience as both an academician and a senior executive in the pharmaceutical industry. He is currently Founder and General Partner, Celtic Therapeutics, L.L.L.P., a private equity firm focused on acquiring projects in mid-stage clinical development, and developing these further to approval for subsequent auction to the pharmaceutical industry. Dr. Corr recently retired from Pfizer Inc, where he was Senior Vice President, Science and Technology, from 2002 to 2006, with responsibility for aligning Pfizer's worldwide research and development organization with licensing activities, science and medical advocacy, global medical relations and science policy. He previously headed Worldwide Research and Development at Pfizer, and prior to that served as Executive Vice President, Pfizer's Global Research and Development, and as President, Worldwide Development. Prior to joining Pfizer, he served as President of Pharmaceutical Research and Development at Warner Lambert/Parke Davis until the merger with Pfizer in 2000. Dr. Corr served previously as Senior Vice President, Discovery Research, at Monsanto/Searle. He came to the private sector after spending 18 years as a researcher in molecular biology and pharmacology at Washington University in St. Louis, where he was a professor in the Departments of Medicine (Cardiology) and Pharmacology and Molecular Biology. Dr. Corr also serves on a number of for-profit and not-for-profit boards and councils. His research is published in more than 160 scientific manuscripts.